HISTOGENEX N.V. - BE 

Ranking results:

Past rankings:

Ranking timeline:

Project Participation Performance(2010-01-01 - 2024-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 2
As coordinator: 0
As participant: 2
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2022 0 2.331.266 0 1
2015 0 3.086.436 0 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:
UNIVERSITEIT ANTWERPEN2
ACADEMISCH ZIEKENHUIS LEIDEN1
BAYER1
BIOMAX INFORMATICS1
CELLPLY1
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS1
CROMED KUTATO ES SZOLGALTATO KOZPONTOK KFT1
DEHNE MATTHIAS1
DRESDEN UNIVERSITY OF TECHNOLOGY1
EIPG1
EUROPEAN CANCER PATIENT COALITION1
FACULDADE DE FARMACIA DA UNIVERSIDADE DE LISBOA1
FOX BIOSYSTEMS NV1
HELMHOLTZZENTRUM DRESDENROSSENDORF EV1
INSEL GRUPPE1
JOHANNES GUTENBERG UNIVERSITAET MAINZ1
KEMOTECH1
LINKCARE HEALTH SERVICES SL1
PHARMINTRACO1
PPD1
QUINTESSENCE CONSULTING1
SCV1
SEMMELWEIS UNIVERSITY OF MEDICINE1
UNIVERSIDAD AUTONOMA DE MADRID1
UNIVERSITA DEGLI STUDI DI MILANO1
UNIVERSITAET BERN1
UNIVERSITAT DE BARCELONA1
UNIVERSITY OF ABERDEEN1
UNIVERSITY OF BOLOGNA1
UNIVERSITY OF COPENHAGEN1

Constancy:

Total number of partners: 31
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 31
Frequent / Rare Partner Ratio: 0

Project overview:

Start dateProjectacronymrolefundingpartners
2022-09-01Protease‐guided tumor targeting tools to revolutionize cancer diagnosis and treatment. OncoProToolsparticipant2.331.26620
2015-09-01Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study MOGLYNETparticipant3.086.43613